AstraZeneca (AZN) Q3 FY25 earnings call: guidance and Q&A

How confident is AZ that the US government deal removes the overhang, and is the $10B catalyst opportunity part of or incremental to the $80B ambition?

Pascal said all four points in the President's letter (Medicaid, price equalization, DTC, returning some price increases) are addressed and AZ expects nothing further, though it cannot guarantee government behavior. The $10B is a risk-adjusted peak-year number that is PART of the $80B, not additive, and he flagged a further ~$11B risk-adjusted from 2026 readouts if positive.

“On the $10 billion, this is part of our $80 billion. This is, by the way, not a 2030 number. It's a peak year revenue number. It's a risk adjusted $10 billion.”

asked by Michael Leuchten · answered by Pascal Soriot

Comfort with 2026 consensus margin at the 34% low end and the pushes/pulls; and whether Roche's persevERA (giredestrant) is a good read-across to camizestrant's SERENA program.

Aradhana named Farxiga LOE (US and China) as the key 2026 headwind, offset by growth-brand momentum and new launches (baxdrostat, cami, dato), with continued R&D investment toward the high end of 20%; she declined to endorse a specific margin figure pending budgeting. Susan argued camizestrant has shown the best oral-SERD profile (best hazard ratios in SERENA-2/6), that first-line enriches for endocrine-sensitive patients where degradation still benefits wild-type, and that SERENA-4 is larger than persevERA and designed to optimize for success.

“The key headwind in 2026 will really be the loss of Farxiga in both U.S. as well as China.”

asked by Sarita Kapila · answered by Aradhana Sarin

Will consensus baxdrostat expectations (~$2B) rise materially post-Bax24, and is Europe waking up to pay for innovation?

Pascal and Ruud were highly enthusiastic, stressing baxdrostat's 60-65% aldosterone reduction (with potential organ-protection benefit) and 24-hour BP control, but Ruud declined to formally raise above the $5B peak, noting seven studies and a dapagliflozin fixed-dose combo could make it $5B or 'perhaps even $10B.' On Europe, Pascal argued innovative-pharma budgets have fallen to ~7% (UK) and must rebalance or Europe risks losing manufacturing and supply-chain control to the US and China.

“whether it is $5 billion or perhaps even $10 billion. Time well tell. But there is an enormous amount of excitement... you will see a renaissance of the treatment of hypertension with a product like baxdrostat.”

asked by Peter Verdult · answered by Ruud Dobber

Will underlying growth slow in 2026 as the 2025 free-drug-to-commercial patient bolus (from lower Part D co-pays) runs out, and which products are most exposed?

Dave said Q1 2026 vs 2025 will be a cleaner apples-to-apples comparison since both include the Part D liability, and patients who switched from free drug to commercial (notably long-duration orals Tagrisso, Calquence, Lynparza) should keep contributing TRx. The one-time prevalent-pool bolus from the co-pay cap dropping into the ~$2,000 range may not repeat, but new patients and new indications should drive continued oral growth.

“The bolus patients who would have been your prevalent pool who came on as the co-pay cap went from the mid-300s down into the 2,000s. We may not see that repeat. But I really do think we're going to see demand coming forward from new patients, new indications.”

asked by Matthew Weston · answered by David Fredrickson

How is AZ targeting its oral and amylin obesity assets amid a shifting competitive landscape, and what is the fastest route to market and differentiation for the CD19/BCMA CAR-T (AZD0120)?

Sharon detailed three Phase II weight-management molecules — AZD5004 (oral), AZD6234 (long-acting amylin) and ACD9550 (dual GLP-1/glucagon) — saying no red flags to date, that Lilly's eloralintide data reinforce selective-amylin potential, and Phase III decisions come in 2026 pending competitor data. Susan said AZD0120 (FasTCAR-manufactured) showed impressive response and complete-response rates in later-line, triple-class-refractory patients (many with prior BCMA CAR-T), all MRD-evaluable patients achieved MRD negativity, and safety showed no Grade 3 CRS and no ICANS; Phase III starts next year across multiple myeloma settings.

“We have no Grade 3 CRS and no ICANS in the dataset that we've presented in the abstract... related in part to the FasTCAR manufacturing, which Gracell had developed.”

asked by Sachin Jain · answered by Susan Galbraith

What does Datroway's better TB02 tolerability imply for its other trials and ADC programs, and how durable is Imfinzi's growth runway?

Susan attributed Datroway's differentiated bone-marrow-toxicity profile to linker stability (delivering more payload to tumor, less peripheral exposure), boosting confidence in TROPION-Breast03/04/05 and the AVANZAR lung studies. Dave said Imfinzi's growth is driven by ADRIATIC (small cell), AEGEAN (early lung) and NIAGARA (bladder), with MATTERHORN and POTOMAC providing further catalysts; despite competition, first-mover advantage and differentiation should sustain the trajectory.

“the Imfinzi trajectory is one that has been both strong and I anticipate will be sustained.”

asked by Richard Vosser · answered by David Fredrickson

Is the $3-5B Calquence peak still achievable given competitor data and the 2027 IRA negotiated price, and was that price in line with expectations?

Dave declined to disclose the Calquence IRA negotiated price (public later this quarter) but said AZ had already assumed Calquence would be an IPA when it set the 2030 ambition in 2024, so the outcome is consistent; positive AMPLIFY data and better-than-expected US volume growth make it positive news, with the frontline finite BTK/BCL-2 opportunity still ahead.

“we will share the IRA negotiated price on Calquence once that's public, which will be happening later this quarter.”

asked by Steve Scala · answered by David Fredrickson

Will DESTINY-Breast09 and DB05/DB11 approvals drive an immediate 2026-27 step-up, and is peak breast-cancer penetration near by 2030?

Dave said DB09 opens the larger first-line metastatic population (where fewer patients reach later lines) with long PFS/treat-to-progression durations and no cumulative toxicity, while DB05/DB11 represent a blockbuster early-stage opportunity; uptake will follow guideline inclusion (NEJM publication recent), so growth builds as guidelines and publications catch up rather than an instant step change.

“DB05 and DB11 in early stage, they represent a blockbuster opportunity together.”

asked by Rajan Sharma · answered by David Fredrickson

Given the unprecedented success rate, is $80B now conservative, and how does the success mix affect profitability and the 50% ex-US split?

Pascal insisted $80B remains ambitious, not soft, given inherent readout risk, and declined to commit to any profitability trajectory: while Specialty Care products lift profitability, weight-loss/metabolic programs require heavy investment, and AZ intends to keep spending R&D in the low 20s to fund its technology platforms (cell therapy, T-cell engagers, radioligands).

“Not long ago, people were thinking the $80 billion was not achievable. Now it's going to be a soft goal. It remains an ambitious goal... it's a risky business.”

asked by Luisa Hector · answered by Pascal Soriot